EP0620739A4 - Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists. - Google Patents

Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.

Info

Publication number
EP0620739A4
EP0620739A4 EP93921562A EP93921562A EP0620739A4 EP 0620739 A4 EP0620739 A4 EP 0620739A4 EP 93921562 A EP93921562 A EP 93921562A EP 93921562 A EP93921562 A EP 93921562A EP 0620739 A4 EP0620739 A4 EP 0620739A4
Authority
EP
European Patent Office
Prior art keywords
necrosis factor
tumor necrosis
factor antagonists
treating tnf
dependent inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93921562A
Other versions
EP0620739A1 (en
Inventor
Craig A Smith
Cindy A Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0620739(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of EP0620739A1 publication Critical patent/EP0620739A1/en
Publication of EP0620739A4 publication Critical patent/EP0620739A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP93921562A 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists. Withdrawn EP0620739A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94623692A 1992-09-15 1992-09-15
US946236 1992-09-15
PCT/US1993/008666 WO1994006476A1 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists

Publications (2)

Publication Number Publication Date
EP0620739A1 EP0620739A1 (en) 1994-10-26
EP0620739A4 true EP0620739A4 (en) 1997-01-15

Family

ID=25484181

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93921562A Withdrawn EP0620739A4 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.

Country Status (8)

Country Link
EP (1) EP0620739A4 (en)
JP (1) JPH07504203A (en)
KR (1) KR100232688B1 (en)
AU (1) AU670125B2 (en)
CA (1) CA2123593C (en)
NO (1) NO941780L (en)
NZ (1) NZ256293A (en)
WO (1) WO1994006476A1 (en)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DE59010941D1 (en) * 1989-04-21 2005-03-24 Amgen Inc TNF receptor, TNF-binding proteins and DNAs coding therefor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
JPH09508140A (en) * 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー Pharmaceutical composition containing chimeric TNF binding protein
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
CA2212006A1 (en) * 1995-02-03 1996-08-08 G.D. Searle & Co. Novel c-mpl ligands
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
EP0839046B1 (en) * 1995-07-14 2002-01-23 Applied Research Systems ARS Holding N.V. Tnf receptor and steroid hormone dhea in a combined therapy
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
JP2000510113A (en) * 1996-05-08 2000-08-08 エフ・ホフマン―ラ ロシュ アーゲー Treatment of asthma with TNFR-Ig
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP2001513754A (en) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Combination therapy using TNF binding proteins for treating TNF-mediated diseases
SI0942740T1 (en) * 1996-12-06 2003-12-31 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
WO1998051344A1 (en) * 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
WO1999003999A1 (en) * 1997-07-17 1999-01-28 The Regents Of The University Of Michigan Methods and compositions for inhibiting the proinflammatory response
US6500431B1 (en) * 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1206275B1 (en) * 1998-11-05 2007-09-05 Omeros Corporation Irrigation solution and method for inhibition of pain and inflammation
TR200504220T2 (en) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Active lymphotoxin-beta receptor immunoglobulin chime A method for high level expression and purification of purified protein proteins and a method for purification of active lymphotoxin-beta receptor immunoglobulin chimeric proteins.
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
EP1165116A1 (en) * 1999-04-02 2002-01-02 Immunex Corporation Use of soluble tumor necrosis factor receptor for treating heart failure
DK1180159T3 (en) * 1999-05-28 2008-11-17 Targeted Genetics Corp Methods and Compositions to Lower the Level of Tumor Necrosis Factor (TNF) in TNF-Associated Disorders
EP1939300A1 (en) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
EP1200127B1 (en) * 1999-07-21 2008-06-25 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US6521422B1 (en) 1999-08-04 2003-02-18 Amgen Inc. Fhm, a novel member of the TNF ligand supergene family
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040136990A1 (en) 2002-07-19 2004-07-15 Abbott Biotechnology Ltd. Treatment of pain using TNFalpha inhibitors
CA2495663A1 (en) * 2002-08-16 2004-02-26 Wyeth Compositions and methods for treating rage-associated disorders
EP1546329A4 (en) * 2002-09-13 2006-07-12 Univ Queensland Gene expression system based on codon translation efficiency
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
JP4980048B2 (en) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム Liquid formulation of tumor necrosis factor binding protein
EP1688439A4 (en) * 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk Fused protein composition
TWI439284B (en) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating tnfα-related disorders
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
EP2845865A1 (en) * 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
AU2006230419A1 (en) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
CN101500607B (en) 2005-05-16 2013-11-27 阿布维生物技术有限公司 Use of TNFalpha inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7919264B2 (en) 2005-11-01 2011-04-05 Abbott Biotechnology Ltd. Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
AU2007309650A1 (en) * 2006-02-08 2008-05-02 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US7972599B2 (en) 2006-03-20 2011-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
RU2466740C2 (en) 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Antibody purification
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
EP2666478A3 (en) 2006-04-10 2014-10-22 AbbVie Biotechnology Ltd Uses and compositions for treatment of psoriasis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
CN103316402A (en) 2006-06-30 2013-09-25 艾伯维生物技术有限公司 Automatic injection device
CN101541825B (en) * 2006-08-28 2013-08-14 阿雷斯贸易股份有限公司 Process for the purification of Fc-fusion proteins
PL2061803T5 (en) 2006-08-28 2023-03-27 Ares Trading S.A. Process for the purification of fc-containing proteins
JP2010501622A (en) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Purification method of Fc-fusion protein
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
KR20090071652A (en) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 Treatment of demyelinating disorders with soulble lymphotoxin-beta-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
WO2008150491A2 (en) 2007-05-31 2008-12-11 Abbott Laboratories BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd Methods for treating juvenile idiopathic arthritis
CN101842382A (en) 2007-06-14 2010-09-22 卡拉狄加制药公司 PAGE fusion proteins
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
CA2736580A1 (en) * 2008-08-12 2010-02-18 Avesthagen Limited An expression vector and a method thereof
AU2009333489A1 (en) 2008-12-30 2010-07-08 Centocor Ortho Biotech Inc. Serum markers predicting clinical response to anti-TNF antibodies in patients with ankylosing spondylitis
SG175279A1 (en) 2009-04-29 2011-11-28 Abbott Biotech Ltd Automatic injection device
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JP2013512674A (en) 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Compositions and methods for increasing the serum half-life of an Fc fusion protein
WO2011075578A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of treating interstitial cystitis
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
HUE046670T2 (en) 2010-01-15 2020-03-30 Kirin Amgen Inc Anti il-17ra antibody formulation and therapeutic regimens for treating psoriasis
MX2012008985A (en) 2010-02-02 2012-09-07 Abbott Biotech Ltd Methods and compositions for predicting responsiveness to treatment with tnf-î± inhibitor.
ES2727275T3 (en) 2010-04-21 2019-10-15 Abbvie Biotechnology Ltd Automatic portable injection device for controlled release of therapeutic agents
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
LT2575884T (en) 2010-06-03 2018-09-25 Abbvie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
FR2962335B1 (en) 2010-07-12 2013-01-18 Cll Pharma USE OF PAT NONAPEPTIDE IN THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES
WO2012019099A2 (en) 2010-08-05 2012-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Follistatin-like-protein-1 as a biomarker for inflammatory disorders
CA2825316C (en) 2011-01-24 2020-05-05 Abbvie Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
CA2829773A1 (en) 2011-03-18 2012-09-27 Abbvie Inc. Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof
CN105413022A (en) 2011-03-29 2016-03-23 艾伯维公司 Improved Shroud Deployment In Automatic Injection Devices
CA2832729A1 (en) 2011-04-21 2012-10-26 Abbvie Inc. Wearable automatic injection device for controlled administration of therapeutic agents
UY34105A (en) 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions and methods for increasing serum half-life
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Compositions for the treatment of rheumatoid arthritis and methods of using same
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
SG11201401562RA (en) 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
KR101525919B1 (en) * 2012-05-11 2015-06-03 가톨릭대학교 산학협력단 Bispecific antibody based on TNFR2 for preventing and traeating autoimmune disease
ES2657377T3 (en) 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept folded correctly with high purity and excellent performance
AU2015241373B2 (en) 2014-03-31 2020-11-05 Amgen K-A, Inc. Methods of treating nail and scalp psoriasis
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
EP3236990B1 (en) 2014-12-22 2020-09-02 Ares Trading S.A. Liquid pharmaceutical composition
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
WO2017177179A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
BR112019011689A2 (en) 2016-12-14 2019-10-22 Progenity Inc treating a gastrointestinal tract disease with a tnf inhibitor
JOP20190162A1 (en) 2016-12-30 2019-06-27 Biocad Joint Stock Co Aqueous Pharmaceutical Composition of a Recombinant Monoclonal Antibody to TNF?
WO2019246313A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20220339169A1 (en) 2018-07-03 2022-10-27 Novartis Ag Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
MX2021002422A (en) 2018-08-29 2021-07-15 Regeneron Pharma Methods and compositions for treating subjects having rheumatoid arthritis.
CA3128212A1 (en) 2019-01-31 2020-08-06 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
CN110964119A (en) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 Anti-malarial dimeric immunoadhesin, pharmaceutical composition and use
EP4261222A1 (en) 2020-12-09 2023-10-18 HK inno.N Corporation ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFalpha BISPECIFIC ANTIBODY, AND USES THEREOF

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003553A1 (en) * 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
WO1992013095A1 (en) * 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0662834A4 (en) * 1992-09-22 1996-04-17 Cell Therapeutics Inc Novel epoxide-containing compounds.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003553A1 (en) * 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
WO1992013095A1 (en) * 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOHLER K M ET AL: "COUNTERACTING THE EFFECTS OF TNF WITH SOLUBLE TNF RECEPTORS.", KEYSTONE SYMPOSIUM ON CYTOKINES AND CYTOKINE RECEPTORS: FROM CLONING TO THE CLINIC, KEYSTONE, COLORADO, USA, JANUARY 31-FEBRUARY 7, 1993. J CELL BIOCHEM SUPPL 0 (17 PART B). 1993. 56, XP002015787 *
MOHLER K M ET AL: "IMMUNOTHERAPEUTIC POTENTIAL OF SOLUBLE CYTOKINE RECEPTORS IN INFLAMMATORY DISEASE.", 1992 MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY (FASEB), PART I, ANAHEIM, CALIFORNIA, USA, APRIL 5-9, 1992. FASEB (FED AM SOC EXP BIOL) J 6 (4). 1992. A1123, XP002015786 *
See also references of WO9406476A1 *

Also Published As

Publication number Publication date
AU670125B2 (en) 1996-07-04
NO941780L (en) 1994-07-15
NZ256293A (en) 1997-06-24
NO941780D0 (en) 1994-05-11
CA2123593C (en) 2000-03-14
CA2123593A1 (en) 1994-03-31
JPH07504203A (en) 1995-05-11
EP0620739A1 (en) 1994-10-26
WO1994006476A1 (en) 1994-03-31
AU4920993A (en) 1994-04-12
KR100232688B1 (en) 1999-12-01

Similar Documents

Publication Publication Date Title
EP0620739A4 (en) Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
ZA93811B (en) Methods of treating inflammatory dermatoses.
HU9400829D0 (en) Tumor necrosis factor muteins
GB2267508B (en) Water treatment method
GB2265399B (en) Horizontal well treatment method
ZA937340B (en) Method of combining polymers
GB2275683B (en) Tumor necrosis factor muteins
GB9215042D0 (en) Microwave treatment apparatus
AU3973793A (en) Method of treating cancer
AU7128494A (en) Gelatinase antagonists used for treating cancer
EP0663210A3 (en) Tumor necrosis factor production inhibitors.
ZA918116B (en) Inhibitors for the formation of tumor necrosis factor,processes for the preparation thereof and the use thereof
ZA936166B (en) Methods of treating cancer
EP0654996A4 (en) Methods of treating psoriasis employing substituted azaspiranes.
EP0609358A4 (en) Methods for treatment of hyperlipidemia using azaspiranes.
GB9202196D0 (en) Method of treatment
EP0609335A4 (en) Methods for the treatment of hyperlipidemia using azaspiranes.
AU663369B2 (en) Method of treating GAR-transformylase-dependent tumors
GB9201391D0 (en) Method of treatment
GB9218597D0 (en) Novel method of treatment
EP0705104A4 (en) Method of cancer treatment
GB9222845D0 (en) Method of treating acid waters
ZA922012B (en) New method of treatment for prostatic cancer
GB9226252D0 (en) Method of treatment
GB9207275D0 (en) Method of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19961127

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19970228

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980103